In ovarian cancer, analysis of samples from the ARIEL2 trial of rucaparib maintenance therapy found RAD51C and RAD51D mutations as well as high-level BRCA1 promoter methylation to be associated with PARPi sensitivity (17). The gene discussed is RAD51C; the disease is ovarian cancer.